| Name | GW-766994 |
|---|---|
| Synonyms |
4-{[({[(2S)-4-(3,4-Dichlorobenzyl)-2-morpholinyl]methyl}carbamoyl)amino]methyl}benzamide
Z6213K1TPE Benzamide, 4-[[[[[[(2S)-4-[(3,4-dichlorophenyl)methyl]-2-morpholinyl]methyl]amino]carbonyl]amino]methyl]- GW-766994 |
| Description | GW 766994 is a specific and oral chemokine receptor-3 (CCR3) antagonist, which has entered clinical trial for asthma and eosinophilic bronchitis. |
|---|---|
| Related Catalog | |
| Target |
CCR3:7.86 (pKi) |
| In Vitro | GW 766994 is a specific chemokine receptor-3 (CCR3) antagonist, which has entered clinical trial for asthma and eosinophilic bronchitis[1]. GW 766994 (10 μM) reverses CCL11-induced activation of CDK5, phosphorylations of CDK5, GSK3β, and increased phosphorylation of tau in hippocampal neurons[2]. |
| References |
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Boiling Point | 685.8±55.0 °C at 760 mmHg |
| Molecular Formula | C21H24Cl2N4O3 |
| Molecular Weight | 451.346 |
| Flash Point | 368.5±31.5 °C |
| Exact Mass | 450.122559 |
| LogP | 1.50 |
| Vapour Pressure | 0.0±2.1 mmHg at 25°C |
| Index of Refraction | 1.608 |
| Storage condition | 2-8℃ |